In Conversation with Matt Dolan

As a senior research analyst focused on medical technology: (devices and diagnostics) with ROTH Capital Partners, Matt Dolan’s investment views have been cited by a “Who’s Who” of publications on Wall Street. Prior to joining Roth in 2003, Mr. Dolan, a graduate of Northwestern University, formed a trading group at the Chicago Board of Trade [...]

enGene initiates $20 million financing to advance lead product

Closely held enGene of Vancouver is working on a financing of up to $20 million with venture capital funds to conduct the first two phases of human clinical trials of its intestinal immunotherapy platform to treat ulcerative colitis, a major subtype of Inflammatory Bowel Disease (IBD). “We have built significant momentum for the financing in [...]

Alitair builds value without outside investors

Dr. William W. Howard likes to say there’s a lesson to be learned in how closely held Alitair Pharmaceuticals has spent the first couple years of its existence developing a portfolio of respiratory therapeutics and a drug safety technology: make some money first and then go out and get investors. “We’ve been able to develop [...]

Novadaq partnering strategy hits marketing milestone

Novadaq Technologies (TSX:NDQ), a maker of real-time fluorescence imaging products for the operating room, reached a significant milestone earlier this month when it named MAQUET Cardiovascular as the exclusive distributor of its CO2 Heart Laser system in the U.S. “We have now completed our strategic agenda of partnering each one of our first four surgical [...]

Cynapsus readies first human data of sublingual strip for PD

Cynapsus Therapeutics (TSX-V:CTH) is set to release human proof-of-concept data of its sublingual thin film-strip as a treatment for motor fluctuations, or episodes of immobility, in patients with Parkinson’s disease. “This will represent an important de-risking event for the project,” CEO Anthony Giovinazzo says in an exclusive interview with BioTuesdays.com, referring to the company’s APL-130277 [...]

Season’s Greetings (and JPM)

Dear Readers, Wow!  What an interesting year 2011 turned out to be. The BioTuesdays.com team – Len, Maria, Jen, Suh, Shelly, Greg and I – would like to wish you all a safe and happy holiday season.  We are taking a short break to spend time with family and friends. But, we will be back [...]

Northwest Biotherapeutics nearing inflection point

After 15 years of research and clinical testing, Northwest Biotherapeutics (OTCBB:NWBO) is nearing an inflection point in its development of an immunotherapeutic cancer vaccine. “We are entering the home stretch in testing our lead program for the most lethal form of brain cancer, which should reach its primary endpoint in the neighborhood of 18 months,” [...]

TearLab taps social media for dry eye awareness

During the past six months, TearLab (NASDAQ:TEAR;TSX:TLB) has initiated a series of social media campaigns as part of an innovative strategy to increase the awareness of dry eye disease (DED) with both patients and doctors. The program is also designed to demonstrate how its diagnostic test for dry eye can change the paradigm of dry [...]

Amorfix turnaround builds broad pipeline

What a difference a year makes. In 2010, Amorfix Life Sciences (TSX:AMF) pulled the plug on its lead blood test to detect the human variant of Creutzfeldt-Jakob disease, thereby halving its stock price and prompting a management shakeup. Today, Amorfix has built an innovative, early-stage product pipeline, including diagnostics and therapeutics for neurodegenerative diseases and [...]

Cellceutix’s potential breakthrough in cancer research

Cellceutix (OTCBB:CTIX) of Beverly, Mass. believes it has found the Holy Grail in cancer research: a compound that activates a tumor suppressor protein known as p53, long regarded as possibly holding the key to future cancer therapies. “Our Kevetrin drug reactivates p53 to its normal function of dictating whether to fix the cell or kill [...]

Next Page »